Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

被引:80
作者
Monami, Matteo [1 ]
Luzzi, Chiara [1 ]
Lamanna, Caterina [1 ]
Chiasserini, Veronica [1 ]
Addante, Filomena [1 ]
Desideri, Carla Maria [1 ]
Masotti, Giulio [1 ]
Marchionni, Niccolo [1 ]
Mannucci, Edoardo [1 ]
机构
[1] Univ Florence, Dept Crit Care Med & Surg, Unit Gerontol & Geriatr, I-50134 Florence, Italy
关键词
diabetes mellitus; insulin secretagogues; metformin; mortality;
D O I
10.1002/dmrr.642
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several studies have shown an increase of mortality in diabetic patients treated with combinations of sulphonylureas and biguanides. Comparisons between different insulin secretagogues in combination with metformin with respect to all-cause mortality have not been reported so far. Methods An observational cohort study was performed on a consecutive series of 2002 outpatients with type 2 diabetes mellitus. Of these patients, 696 (34.8%) were receiving combinations of insulin secretagogues and biguanides at enrolment. Three-year mortality was assessed through research in the City of Florence Registry Office. Results During follow-up, 295 deaths were recorded. Among patients on combined secretagogue and biguanide treatment, glibenclamide was associated with a significantly higher yearly mortality (8.7%) than repaglinide (3.1%; p = 0.002), gliclazide (2.1%; p = 0.001), and glimepiride (0.4%; p < 0.0001). After adjusting for potential confounders (including age; duration of diabetes; Body Mass Index (BMI); lipid profile; HbA(1c); insulin treatment; metformin doses; Charlson co-morbidity score; CCS), mortality remained significantly higher in patients treated with combinations of glibenclamide and metformin when compared to those treated with different insulin secretagogues (OR with 95% CI: 2.09 [1.07;4.11]). Conclusions In the present study, sulphonylureas with greater selectivity for p-cell receptors, such as glimepiride and gliclazide, were associated with a lower mortality when used in combination with metformin in comparison with glibenclamide. Safety of such combinations deserves further investigation. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:477 / 482
页数:6
相关论文
共 21 条
[1]  
Blackburn H, 1969, J Electrocardiol, V2, P305
[2]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[3]  
Chalmers J, 1999, CLIN EXP HYPERTENS, V21, P1009
[4]   VALIDATION OF A COMBINED COMORBIDITY INDEX [J].
CHARLSON, M ;
SZATROWSKI, TP ;
PETERSON, J ;
GOLD, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) :1245-1251
[5]   Improved clinical outcomes associated with metformin in patients with diabetes and heart failure [J].
Eurich, DT ;
Majumdar, SR ;
McAlister, FA ;
Tsuyuki, RT ;
Johnson, JA .
DIABETES CARE, 2005, 28 (10) :2345-2351
[6]   Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up [J].
Fisman, EZ ;
Tenenbaum, A ;
Boyko, V ;
Benderly, M ;
Adler, Y ;
Friedensohn, A ;
Kohanovski, M ;
Rotzak, R ;
Schneider, H ;
Behar, S ;
Motro, MT .
CLINICAL CARDIOLOGY, 2001, 24 (02) :151-158
[7]   Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes [J].
Garber, AJ ;
Donovan, DS ;
Dandona, P ;
Bruce, S ;
Park, JS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08) :3598-3604
[8]  
Gavin JR, 1997, DIABETES CARE, V20, P1183
[9]   Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide [J].
Gribble, FM ;
Ashcroft, FM .
DIABETOLOGIA, 1999, 42 (07) :845-848
[10]   Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study [J].
Gulliford, M ;
Latinovic, R .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2004, 20 (03) :239-245